Results 11 to 20 of about 1,721 (143)
Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial [PDF]
ESC Heart FailureAims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF.
Veraprapas Kittipibul +13 more
doaj +3 more sources
Therapeutic Impact of Vericiguat on Ventricular Remodeling in a Pressure-Overload Heart Failure Model [PDF]
LifePressure-overload-induced heart failure is characterized by pathological ventricular remodeling, including hypertrophy and fibrosis, which compromise cardiac function and worsen outcomes.
Wen-Rui Hao +6 more
doaj +3 more sources
Mediators of Inflammation, 2022 Bone homeostasis has been a dynamic equilibrium between osteoclasts (OCs) and osteoblasts (OBs). However, excessive activation of OCs could disturb the bone homeostasis. As a result, effective medical interventions for patients are greatly demanding.
Kaiqiang Sun +7 more
doaj +2 more sources
Clinical and Translational Science, 2022 Vericiguat was developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event.
Michael Boettcher +11 more
doaj +2 more sources
Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States [PDF]
Frontiers in Cardiovascular MedicineAimsThis study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world settings.MethodsWe ...
Stephen J. Greene +7 more
doaj +2 more sources
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
Journal of Pharmacy and Bioallied SciencesIntroduction: Heart failure (HF) with reduced ejection fraction (EF) poses high morbidity and mortality. Guidelines Directed Medical Therapy (GDMT) is essential, yet many patients experience significant symptoms.
Pushpraj Patel +4 more
doaj +2 more sources
Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China
Reviews in Cardiovascular MedicineBackground: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world ...
Qi Wang +13 more
doaj +2 more sources
Vericiguat: A New Hope for Heart Failure Patients
Cardiovascular Therapeutics, 2022 Heart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse vital tissues.
Raquel Chiles, Rami A. Al-Horani
doaj +2 more sources
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice
Reviews in Cardiovascular MedicineHeart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortality. Despite advancements in guideline-directed medical therapy (GDMT), many
Lucia Tricarico +4 more
doaj +2 more sources
Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
BiomedicinesBackground/Objectives: Pulmonary hypertension is a progressive disease leading to right heart failure. One treatment strategy is to induce vasodilation via the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) signaling ...
Katharina Nubbemeyer +6 more
doaj +2 more sources